A five-CpG signature of microRNA methylation in non-G-CIMP glioblastoma.

摘要: Aims DNA methylation has been found to regulate microRNAs (miRNAs) expression, but the prognostic value of miRNA-related aberration remained largely elusive in cancers including glioblastomas (GBMs). This study aimed investigate clinical and biological feature miRNA GBMs non-glioma-CpG island methylator phenotype (non-G-CIMP). Methods Prognostic loci were analyzed, with TCGA Rennes cohort as training sets, independent datasets low-grade gliomas (LGGs) obtained validation sets. Different statistical bioinformatic analysis experimental validations performed clinically biologically characterize signature. Results We identified validated a risk score based on status five miRNA-associated CpGs which could predict survival GBM patients series signature was age O-6-methylguanine-DNA methyltransferase (MGMT) promoter status. The subgroup associated angiogenesis accordingly differential responses bevacizumab-contained therapy. MiRNA target vitro experiments further confirmed accuracy this Conclusion five-CpG relevant potential predictive for GBMs. It might be help improving individualized treatment.